REG - Hemogenyx Pharma Plc - Publication of Prospectus

Hemogenyx PharmaceuticalsAnnouncement

19/11/2025 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251119:nRSS2074Ia&default-theme=true

RNS Number : 2074I  Hemogenyx Pharmaceuticals PLC  19 November 2025

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY IN OR INTO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

 

This announcement is an advertisement and not a prospectus. Neither this
announcement nor anything contained herein shall form the basis of, or be
relied upon in connection with, any offer or commitment whatsoever in any
jurisdiction. Investors should not purchase any transferable securities
referred to in this announcement except on the basis of information contained
in the prospectus (the "Prospectus") in its final form that is published by
Hemogenyx Pharmaceuticals plc in connection with the admission of new ordinary
shares in the capital of the Company (the "New Ordinary Shares") to listing in
equity shares (transition) category of the Official List of the Financial
Conduct Authority (the "FCA") and to trading on the main market for listed
securities (the "Main Market") of London Stock Exchange plc (the "London Stock
Exchange") following conversion of certain convertible loan notes and exercise
of certain warrants.

 

19 November 2025

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

 

Publication of Prospectus

 

The Company is pleased to announce today the publication of a Prospectus in
relation to the admission of 116,982 new ordinary shares of 0.01 pence each to
be issued upon conversion of convertible loan notes issued by the Company on
31 August 2025 (the "Convertible Loan Notes Shares") and 439,629 new ordinary
shares of 0.01 pence each to be issued following the exercise of certain of
the warrants issued by the Company during 2025 (the "Warrant Shares")
(together the "New Ordinary Shares") to listing in the equity shares
(transition) category of the Official List of the FCA and to trading on the
Main Market of the London Stock Exchange (together, "Admission").

 

It is expected that Admission will become effective, and unconditional
dealings in the New Ordinary Shares will commence on 24 November 2025.

 

The Prospectus will be available from the Company's registered office at 6
Heddon Street, London W1B 4BT, United Kingdom and online
at https://hemogenyx.com (https://hemogenyx.com/)  (subject to applicable
securities laws).

 

An electronic copy of the Prospectus will also be submitted to the National
Storage Mechanism and should be available shortly for inspection
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

 

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)

 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl

 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx LLC and
Immugenyx LLC, located in New York City.

 

The Company is a clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as a platform technology that it uses as engines for novel
product development.

 

.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PDIFKLFFEFLZFBE



            Copyright 2019 Regulatory News Service, all rights reserved